Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02683525 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Graft vs Host Disease
Hematopoietic Stem Cell Transplantation

Interventions

DRUG: Sitagliptin

Sponsor

Sherif S. Farag